Generate a tailored SOP for Dr. Peng Xu. Improve your application with a focused, well-structured draft.
I am currently a Postdoctoral Associate at Yale School of Medicine. I obtained my PhD in Medical Systems Biology from Fudan University in January 2022, focusing my doctoral training and research on cancer epigenetics. My work emphasizes histone modification-mediated regulation, DNA methylation, and non-coding RNA regulation under the supervision of Dr. Wenqiang Yu. My PhD thesis investigated the epigenetic regulation of RNA metabolism, particularly how histone modifications influence pre-mRNA alternative splicing. After my PhD, from January to August 2022, I worked at a biomedical start-up as the Director of the Creative R&D Department, leading projects aimed at developing early cancer biomarkers and translating discoveries into commercial diagnostic kits for broader clinical public use. In September 2022, I joined Dr. Qin Yan’s laboratory in the Department of Pathology at Yale School of Medicine as a postdoctoral researcher. My current research focuses on identifying druggable regulators that are critical for cancer metastasis and developing innovative strategies to prevent and treat metastatic tumors.
Yale School of Medicine • New Haven, CT
Research focuses on identifying druggable regulators critical for cancer metastasis and developing innovative strategies for treatment.
Biomedical Start-up •
Led projects aimed at developing early cancer biomarkers and translating discoveries into commercial diagnostic kits.
Administered via the Graduate School of Arts and Sciences (GSAS). GRE General is optional for PhD.